Form4insider filings, from the source

Company · CIK 0001720893 · SIC 2834 — Pharmaceutical Preparations · Nasdaq

BioXcel Therapeutics, Inc. · BTAI

Insider activity reported against this company. All insider holders · On EDGAR ↗

1M3M6M1Y2YAll datashares as filed — not split-adjusted
Open-market buys & salesbuys $111k · 13sales $0 · 0net $111k
$10k$10k$100k$100k$1M$1MbuyssalesNov 28Nov 30Dec 3Dec 6Dec 9Dec 12Dec 15

Reported at this company — common stock

TradeReported (ET)InsiderSharesAvg priceTotalOwned afterΔ stakeFlags
Jun 15, 2026 MForm 4 →Jun 17, 8:01 pm EDTJavier RodriguezSee Remarks35——26,838—
Jun 15, 2026 MForm 4 →Jun 17, 8:00 pm EDTRichard I SteinhartChief Financial Officer35——26,335—
Jun 15, 2026 MForm 4 →Jun 17, 8:00 pm EDTFrank YoccaChief Scientific Officer35——26,210—
Jun 15, 2026 MForm 4 →Jun 17, 8:00 pm EDTVimal MehtaCEO and President, Director219——69,817—
Dec 14, 2018 PForm 4 →Dec 14, 4:30 pm ESTVimal MehtaCEO, President, Secretary, Director2,000$4.38$8,7665,000+66.7% plan?
Dec 6, 2018 PForm 4 →Dec 7, 5:50 pm ESTPeter MuellerDirector8,795$5.01$44,045158,320+5.88% plan?
Dec 4, 2018 PForm 4 →Dec 6, 5:34 pm ESTPeter MuellerDirector4,007$5.13$20,544149,525+2.75% plan?
Dec 4, 2018 PForm 4 →Dec 4, 5:05 pm ESTVimal MehtaCEO, President, Secretary, Director1,000$5.12$5,1203,000+50.0% plan?
Dec 3, 2018 PForm 4 →Dec 6, 6:04 am ESTFrank YoccaChief Scientific Officer900$5.21$4,6921,850+94.7% plan?
Dec 3, 2018 PForm 4 →Dec 4, 10:22 am ESTVimal MehtaCEO, President, Secretary, Director1,000$5.17$5,1652,000+100% plan?
Dec 3, 2018 PForm 4 →Dec 4, 9:49 am ESTRichard I SteinhartChief Financial Officer500$5.20$2,6001,500+50.0% plan?
Nov 30, 2018 PForm 4 →Nov 30, 5:36 pm ESTRichard I SteinhartChief Financial Officer500$5.00$2,5001,000+100% plan?
Nov 30, 2018 PForm 4 →Nov 30, 5:35 pm ESTFrank YoccaChief Scientific Officer450$5.20$2,340950+90.0% plan?
Nov 30, 2018 PForm 4 →Nov 30, 4:10 pm ESTVimal MehtaCEO, President, Secretary, Director1,000$5.10$5,1041,000— plan?
Nov 29, 2018 PForm 4 →Nov 30, 4:17 pm ESTKrishnan NandabalanDirector, 10% Owner1,000$4.92$4,9151,000— plan?
Nov 29, 2018 PForm 4 →Nov 30, 2:31 pm ESTFrank YoccaChief Scientific Officer500$5.02$2,511500— plan?
Nov 29, 2018 PForm 4 →Nov 30, 2:30 pm ESTRichard I SteinhartChief Financial Officer500$5.00$2,500500— plan?

Reported at this company — derivatives (options, RSUs, warrants)

TradeReported (ET)InsiderSharesAvg priceTotalOwned afterΔ stakeFlags
Aug 12, 2026 AForm 4 →Aug 14, 7:00 pm EDTSusan E. AtkinsDirector17,000——17,000—
Jun 15, 2026 MForm 4 →Jun 17, 8:01 pm EDTJavier RodriguezSee Remarks35——212—
Jun 15, 2026 MForm 4 →Jun 17, 8:00 pm EDTRichard I SteinhartChief Financial Officer35——212—
Jun 15, 2026 MForm 4 →Jun 17, 8:00 pm EDTFrank YoccaChief Scientific Officer35——212—
Jun 15, 2026 MForm 4 →Jun 17, 8:00 pm EDTVimal MehtaCEO and President, Director219——1,313—
Mar 12, 2018 AForm 4 →Mar 13, 5:13 pm EDTSandeep LaumasDirector37,209——124,188—
Mar 12, 2018 AForm 4 →Mar 13, 5:12 pm EDTRichard I SteinhartChief Financial Officer32,232——116,130—
Mar 12, 2018 AForm 4 →Mar 13, 5:12 pm EDTPeter MuellerDirector37,209——161,397—
Mar 12, 2018 AForm 4 →Mar 13, 5:11 pm EDTFrank YoccaChief Scientific Officer36,498——185,808—
Mar 12, 2018 AForm 4 →Mar 13, 5:10 pm EDTVincent O'NeillChief Medical Officer31,047——155,472—